Minerva Neurosciences, Inc. (NERV)
2.42
+0.12
(+5.22%)
USD |
NASDAQ |
Nov 06, 16:00
2.415
0.00 (0.00%)
After-Hours: 20:00
Minerva Neurosciences Research and Development Expense (Quarterly) : 5.156M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 5.156M |
| June 30, 2026 | 7.187M |
| March 31, 2026 | 5.255M |
| December 31, 2025 | 2.174M |
| September 30, 2025 | 0.9254M |
| June 30, 2025 | 1.298M |
| March 31, 2025 | 1.362M |
| December 31, 2024 | 1.983M |
| September 30, 2024 | 1.888M |
| June 30, 2024 | 3.860M |
| March 31, 2024 | 4.167M |
| December 31, 2023 | 4.721M |
| September 30, 2023 | 3.444M |
| June 30, 2023 | 1.888M |
| March 31, 2023 | 2.654M |
| December 31, 2022 | 3.190M |
| September 30, 2022 | 2.367M |
| June 30, 2022 | 4.132M |
| March 31, 2022 | 4.960M |
| December 31, 2021 | 18.75M |
| September 30, 2021 | 4.513M |
| June 30, 2021 | 5.521M |
| March 31, 2021 | 3.259M |
| December 31, 2020 | 3.551M |
| September 30, 2020 | 4.639M |
| Date | Value |
|---|---|
| June 30, 2020 | 5.767M |
| March 31, 2020 | 8.082M |
| December 31, 2019 | 9.524M |
| September 30, 2019 | 9.674M |
| June 30, 2019 | 8.320M |
| March 31, 2019 | 11.61M |
| December 31, 2018 | 9.008M |
| September 30, 2018 | 8.370M |
| June 30, 2018 | 9.062M |
| March 31, 2018 | 8.449M |
| December 31, 2017 | 6.541M |
| September 30, 2017 | 8.956M |
| June 30, 2017 | 7.144M |
| March 31, 2017 | 7.614M |
| December 31, 2016 | 6.499M |
| September 30, 2016 | 5.852M |
| June 30, 2016 | 2.714M |
| March 31, 2016 | 5.375M |
| December 31, 2015 | 6.259M |
| September 30, 2015 | 3.828M |
| June 30, 2015 | 4.485M |
| March 31, 2015 | 3.961M |
| December 31, 2014 | 2.969M |
| September 30, 2014 | 24.74M |
| June 30, 2014 | 14.55M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Heron Therapeutics, Inc. | 2.702M |
| Tonix Pharmaceuticals Holding Corp. | 19.42M |
| Karyopharm Therapeutics, Inc. | 28.96M |
| Corbus Pharmaceuticals Holdings, Inc. | 31.18M |
| Ocugen, Inc. | 12.50M |